Stay updated with breaking news from Abstracts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Multiple epcoritamab (DuoBody-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical
Multiple epcoritamab (DuoBody-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several
Oral presentation of pivotal Phase 2 clinical trial of Cami in relapsed or refractory Hodgkin lymphoma ZYNLONTA diffuse large B-cell lymphoma data highlighted in several abstracts ADC Therapeutics
- Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation - - Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented